OrganOx signs 5 year distribution agreement with Dismeval for Spanish distribution of the OrganOx metra device

OrganOx, a leader in the field of organ preservation,  has signed a 5 year agreement with Dismeval to distribute the OrganOx metra in Spain.

" We are delighted to have signed up Dismeval s.l  to ensure the OrganOx metra is adopted in Spain. In terms of organ donation rates Spain leads the rest of the world, very much helped by the opt-out policy which has been in place since 1979.  We have been  impressed with Dismeval's track record over many years in driving other innovative surgical products into the Spanish market. With Dismeval as our partner in Spain we look forward to seeing the positive impact of our technology benefiting all involved in liver transplantation. " said Craig Marshall, CEO of OrganOx Limited.

"We recognise  the potential of the OrganOx metra to further improve the  utilisation of deceased donor livers in Spain. We anticipate first sales into leading Spanish liver transplant hospitals centres in Q4 of 2017" said  Salvador Forés, General Manager of Dismeval s.l.

OrganOx signs 5 year agreement with Avidal Group GmbH for distribution in Germany, Austria and Switzerland

OrganOx, a leader in the field of organ preservation,  has signed a 5 year agreement with Avidal Group GmbH to distribute the OrganOx metra in Germany, Austria and Switzerland.

As part of the agreement Avidal is committed to securing marketing approval for the CE marked metra in each of these 3 countries.

“ We are delighted to have signed up the Avidal Group to ensure the OrganOx metra is adopted in these 3 key European countries. We have been  impressed with Avidal’s track record over many years in driving other innovative surgical and interventional products into these markets. With Avidal as our partner in Germany, Austria and Switzerland we look forward to establishing a significant presence in these countries in the coming years” said Craig Marshall, CEO of OrganOx Limited.

“We recognise  the potential of the OrganOx metra to dramatically improve the  utilisation of deceased donor livers, we see a huge opportunity for this product in the countries we serve. The marketing approval process in Germany is particularly complex, but it a process we at Avidal Group  understand very well, and in the case of the OrganOx metra we actually began this process, in good faith, almost 12 months ago. We anticipate first sales into German liver transplant hospitals centres in Q4 of 2017” said Torsten Heilmann, CEO of Avidal Group GmbH.

OrganOx Supports the Oxford Transplant Foundation

OrganOx is pleased to announce support of a local and very relevant charity, the Oxford Transplant Foundation.  The mission of this charity is to further the science and practice of transplantation, and to provide support for education and training in transplantation, over and above that provided by the University of Oxford and National Health Service.  

Learn more about the foundation HERE. 

Craig Marshall joins OrganOx as CEO

OrganOx is pleased to announce the appointment of Craig Marshall as CEO of OrganOx with effect from 1 January 2017. Craig joins OrganOx from Siemens Magnet Technology in Eynsham where he was the Managing Director since 2010,  with a turnover in excess of £150m and employing over 400 people. Craig will take over as CEO from Dr Les Russell who is moving to the position of Chairman.

 

Craig commented

“I am delighted to be able to take up the role of CEO of OrganOx at such an exciting time as the company transitions to full commercial activities. We have an outstanding team which has developed the world leading product for liver preservation, the OrganOx metra which is transforming liver transplantation around the globe and saving more lives by enabling the transplantation of more organs. I look forward to leading OrganOx to even greater success in the future by ensuring our proprietary technology is adopted by transplant centres in Europe, America and beyond.”

 

New Chairman Dr Les Russell added

“On behalf of our company and investors, it is my pleasure to welcome Craig to the role of CEO. It is a tribute to the team and strength of the company that we are able to recruit such a talented and high calibre individual as Craig. During his time at Siemens, Craig led his business to become a role model for other design and manufacturing businesses, picking up the coveted Factory of the Year award in 2015. I look forward to working with Craig as we drive the company forward on its mission to improve the supply and quality of organs for transplantation worldwide.”

Les and Craig  2.jpeg

OrganOx announces the first US transplant using the metra and initiation of the US Pivotal Study

OrganOx is pleased to announce that the University of Wisconsin, led by Principal Investigator Dr Anthony D’Alessandro, has transplanted the first patients in OrganOx’s pivotal US clinical study using the metra®. This study, operating under an Investigational Device Exemption (IDE) from the FDA, involves the transplant of up to 266 donor livers and is intended to test the safety and effectiveness of the OrganOx metra for preserving human livers prior to liver transplantation against the current standard of static cold storage.

 

Dr Les Russell, CEO of OrganOx commented “I’m delighted that Dr D’Alessandro and the University of Wisconsin have transplanted the first livers in our major study. The University of Wisconsin has a long history in pioneering novel approaches in transplantation and indeed, UW solution remains the most widely used organ preservation solution after more than 20 years in use.”

 

The OrganOx metra is a fully automated and transportable device for ex-vivo normothermic perfusion of donor livers prior to transplantation. The metra is the result of 20 years of research and is based on the pioneering work of Professors Peter Friend and Constantin Coussios at the University of Oxford. The CE marked metra has been used to transplant more than 170 livers in 6 countries. The device was recently used in a pivotal European study (COPE, Consortium for Organ Preservation) funded by the European Union under Framework 7 and the full results of this study are expected to be released shortly.

 

The US study will involve up to 15 major liver transplant centres in the US and is funded by a grant from Innovate UK, under the Biomedical Catalyst Award.

University of Wisconsin Principal Investigator Dr Anthony D'Alessandro and the team with the metra device during the first transplant (photograph courtesy of David Sohl)  

University of Wisconsin Principal Investigator Dr Anthony D'Alessandro and the team with the metra device during the first transplant (photograph courtesy of David Sohl)